Jim Cramer thinks this group will be on fire if you believe that the Fed will no longer be patient with rates.» Read More
This is an unofficial transcript of Warren Buffett's April 23, 2014 live appearance on CNBC's "Closing Bell"
Warren Buffett discusses activist investing and shares his thoughts on David Winters and Bill Ackman.
CNBC's Kate Kelly reports Bill Ackman did the bulk of his buying of Allergan through the off-exchange options market.
Bill Ackman tells CNBC that his losses from betting against Herbalife have been "more than cut in half" based on the recent downturn of the company's stock.
Maybe it was the martini that helped Carl Icahn publicly support longtime nemesis Bill Ackman, but he still calls Marty Lipton "dead wrong."
Happy Wednesday and welcome to the Morning Six-Pack, where we're always trying to beat analyst estimates and surprise to the upside.
Bill Ackman also tells CNBC that Allergan's poison-pill defense doesn't make his takeover bid more difficult.
William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he is helping Valeant buy Allergan.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he decided to team up with Valeant Pharmaceuticals to make a play for Allergan.
The bull market is seeing the equivalent of its first gray hairs and the proof is in Tuesday's blast of merger activity.
Drugmakers eager to satisfy shareholders are wheeling, dealing, and in one case even making trades like a pro sports team looking to shake up its roster.
Considering Cramer is a big fan of M&A, why is he so opposed to the Allergan takeover?
Looking at the modest gains in the Dow and S&P, you wouldn’t think anything big happened in the market. But it did.
U.S. stocks rose on Tuesday after earnings from McDonald's and Netflix.
Virtually every Pershing Square Capital investment appears to have made money this year.
More than half the revenue from Botox comes from therapeutic, not cosmetic, use. And its potential is helping to make Allergan an attractive target.
One astute trader picked up big money overnight by buying options in Furiex Pharmaceuticals.